{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:58:32Z","timestamp":1776272312050,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.radonc.2021.08.013","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T03:10:37Z","timestamp":1630033837000},"page":"128-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy"],"prefix":"10.1016","volume":"163","author":[{"given":"Maria Cristina","family":"Leonardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Arrobbio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-4548","authenticated-orcid":false,"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-2964","authenticated-orcid":false,"given":"Stefania","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"La Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-7471","authenticated-orcid":false,"given":"Sabrina","family":"Kahler-Ribeiro-Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Dicuonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damaris Patricia","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alessia","family":"Zerella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Mazzarol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Lavinia","family":"Travaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-4634","authenticated-orcid":false,"given":"Mattia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2021.08.013_b0005","doi-asserted-by":"crossref","unstructured":"Burstein H..J, Curigliano G., Loibl S., Dubsky P., Gnant M., Poortmans P., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541-1557. doi: 10.1093\/annonc\/mdz235. PMID: 31373601.","DOI":"10.1093\/annonc\/mdz235"},{"key":"10.1016\/j.radonc.2021.08.013_b0010","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clon.2017.06.003","article-title":"Neoadjuvant therapy in early breast cancer: Treatment considerations and common debates in practice","volume":"29","author":"Cain","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2021.08.013_b0025","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0030","unstructured":"Curigliano G., Burstein H.J., Winer E.P., Gnant M., Dubsky P., Loibl S., et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700-1712. doi: 10.1093\/annonc\/mdx308. Erratum in: Ann Oncol. 2018;29(10):2153. Erratum in: Ann Oncol. 2019: Erratum in: Ann Oncol. 2019;30(7):1181. PMID: 28838210; PMCID: PMC6246241."},{"key":"10.1016\/j.radonc.2021.08.013_b0035","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2021.08.013_b0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/tbj.12793","article-title":"Are the ACOSOG Z0011 trial findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy?","volume":"23","author":"Kantor","year":"2017","journal-title":"Breast J"},{"key":"10.1016\/j.radonc.2021.08.013_b0045","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","article-title":"Axillary nodal management following neoadjuvant chemotherapy: A review","volume":"3","author":"Pilewskie","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0050","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/bjs.5209","article-title":"Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer","volume":"93","author":"Xing","year":"2006","journal-title":"Br J Surg"},{"key":"10.1016\/j.radonc.2021.08.013_b0055","doi-asserted-by":"crossref","unstructured":"Mamounas E.P., Brown A., Anderson S., Smith R., Julian T., Miller B., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694-702. doi: 10.1200\/JCO.2005.05.188. Erratum in: J Clin Oncol. 2005;23(21):4808. Sovan, Atilla [corrected to Soran, Atilla]. PMID: 15837984.","DOI":"10.1200\/JCO.2005.05.188"},{"key":"10.1016\/j.radonc.2021.08.013_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","author":"Burstein","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.radonc.2021.08.013_b0065","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s00259-010-1494-1","article-title":"Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy","volume":"37","author":"Gilardi","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2021.08.013_b0070","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0075","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jnci\/91.4.368","article-title":"Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series","volume":"91","author":"Veronesi","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2021.08.013_b0080","doi-asserted-by":"crossref","unstructured":"Bossuyt V., Provenzano E., Symmans W.F., Boughey J.C., Coles C., Curigliano G., et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015;26:1280-91. doi: 10.1093\/annonc\/mdv161. Epub 2015 May 27. PMID: 26019189; PMCID: PMC4804123.","DOI":"10.1093\/annonc\/mdv161"},{"key":"10.1016\/j.radonc.2021.08.013_b0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.radonc.2020.01.018","article-title":"Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03)","volume":"145","author":"Boersma","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0090","unstructured":"Alliance for Clinical Trials in Oncology. Bethesda (MD): National Library of Medicine (US); 2013. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy (ALLIANCE A011202) ClinicalTrials.gov [Internet] [cited 2016 Jun 29] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01901094 NLM Identifier: NCT01901094."},{"key":"10.1016\/j.radonc.2021.08.013_b0095","unstructured":"Donker M., van Tienhoven G., Straver M.E., Meijnen P., van de Velde C.J., Mansel R.E., et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303-10. doi: 10.1016\/S1470-2045(14)70460-7. Epub 2014 Oct 15. PMID: 25439688; PMCID: PMC4291166."},{"key":"10.1016\/j.radonc.2021.08.013_b0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","article-title":"Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000","volume":"20","author":"Sol\u00e1","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/annonc\/mdi089","article-title":"Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy","volume":"16","author":"Veronesi","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.breast.2012.06.013","article-title":"Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND)","volume":"21","author":"Gentilini","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2021.08.013_b0115","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2016.71.0947","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Lyman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0120","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cncr.23481","article-title":"Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy","volume":"112","author":"Jeruss","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2021.08.013_b0125","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.clbc.2017.03.014","article-title":"Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy: nomogram for predicting nonsentinel lymph node metastasis","volume":"17","author":"Ryu","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.radonc.2021.08.013_b0130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10147-012-0418-4","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation","volume":"18","author":"Takei","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","article-title":"Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment","volume":"42","author":"Galimberti","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0140","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2016.12.021","article-title":"Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy","volume":"122","author":"Gentilini","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0150","article-title":"NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy","volume":"23","author":"Tinterri","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.radonc.2021.08.013_b0155","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ejca.2004.04.006","article-title":"Predictors of non-sentinel lymph node metastasis in breast cancer patients","volume":"40","author":"Goyal","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.08.013_b0160","doi-asserted-by":"crossref","unstructured":"Viale G., Maiorano E., Pruneri G., Mastropasqua M.G., Valentini S., Galimberti V., et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319-25. doi: 10.1097\/01.sla.0000150255.30665.52. PMID: 15650643; PMCID: PMC1356918.","DOI":"10.1097\/01.sla.0000150255.30665.52"},{"key":"10.1016\/j.radonc.2021.08.013_b0165","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0175","doi-asserted-by":"crossref","unstructured":"Gooch J., King T.A., Eaton A., Dengel L., Stempel M., Corben A.D., et al. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer. Ann Surg Oncol. 2014;21:2897-903. doi: 10.1245\/s10434-014-3752-0. Epub 2014 Apr 29. PMID: 24777858; PMCID: PMC4346337.","DOI":"10.1245\/s10434-014-3752-0"},{"key":"10.1016\/j.radonc.2021.08.013_b0180","doi-asserted-by":"crossref","unstructured":"Liedtke C., Kolberg H.C., Kerschke L., G\u00f6rlich D., Bauerfeind I., Fehm T., et al. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). Clin Exp Metastasis. 2018;35:777-783. doi: 10.1007\/s10585-018-9938-2. Epub 2018 Oct 15. PMID: 30324492.","DOI":"10.1007\/s10585-018-9938-2"},{"key":"10.1016\/j.radonc.2021.08.013_b0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy","volume":"170","author":"Haque","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.radonc.2021.08.013_b0190","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/SLA.0000000000002373","article-title":"Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance)","volume":"266","author":"Boughey","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2021.08.013_b0195","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.08.013_b0200","doi-asserted-by":"crossref","unstructured":"de Boniface J., Frisell J., Andersson Y., Bergkvist L., Ahlgren J., Ryd\u00e9n L., et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379. doi: 10.1186\/s12885-017-3361-y. PMID: 28549453; PMCID: PMC5446737.","DOI":"10.1186\/s12885-017-3361-y"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021067074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021067074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:19:10Z","timestamp":1759123150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814021067074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"alternative-id":["S0167814021067074"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2021.08.013","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2021.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}